- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02848794
Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma
Phase I/IIa, Single-Arm, Open Study of Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma
Study Overview
Detailed Description
Gliomas account for almost 80% of primary malignant brain tumors, and glioblastoma is the most common subtype. Despite treatment with surgery, radiation, and chemotherapy(Temozolomide) almost all patients with glioma experience recurrence and the median survival for most patients is less than 2 years. In recurrent disease, salvage therapies have been limited and result in minimal improvement in OS. This overwhelming need for improved treatments has driven the development of novel drugs that target glioma biology, specifically anti-VEGF therapies.
Malignant gliomas are considered among the most angiogenic of cancers and are mostly fueled by vascular endothelial growth factor (VEGF) signaling via its endothelial tyrosine kinase receptor VEGF receptor 2 (VEGFR2). Levels of VEGF and its receptor are correlated with the histologic grade of gliomas, with the highest levels present in glioblastoma.Thus glioblastoma has emerged as an attractive tumor in which to conduct clinical trials of novel anti-VEGF agents, such as monoclonal antibodies and tyrosine kinase inhibitors.
Bevacizumab is a recombinant humanized monoclonal antibody that binds all VEGF isoforms, causing reduced tumor vascularization and inhibiting tumor growth. In a single-institute, phase II trial of patients with recurrent high-grade glioma, bevacizumab in combination with irinotecan demonstrated 46% 6-month PFS and 57% OR rates. Following on from the results of this study, another phase II trial was conducted to evaluate the safety and efficacy of bevacizumab alone and in combination with irinotecan, again showing promising results. On the basis this study, as well as a study by Kreisl and colleagues, FDA has approved to bevacizumab for patients with recurrent glioblastoma in 2009. Despite bevacizumab therapy, 6-month progression-free survival (PFS) for relapsed or progressive high-grade gliomas is 30.8% to 50.3%, and median overall survival (OS) is less than 42 week. Thus, recurrent high-grade gliomas remains a largely unmet medical need, which highlights the need for novel and effective therapies.
Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to and strongly inhibits vascular endothelial growth factor receptor 2 (VEGFR-2). Apatinib has been demonstrated as monotherapy prolongs OS in patients with gastric or gastroesophageal junction adenocarcinoma after two or more lines of chemotherapy with moderate, reversible, and easily managed adverse events.
The study is aimed to evaluate the efficacy and safety of Apatinib and Irinotecan in patients with recurrent high-grade glioma.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Tao Yang, Master
- Phone Number: +86018961327792
- Email: 18961327792@163.com
Study Locations
-
-
Jiangsu
-
Lianyungang, Jiangsu, China, 222000
- Recruiting
- The First's People Hospital of Lianyungang
-
Contact:
- Tao Yang, Master
- Phone Number: +86018961327792
- Email: 18961327792@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with histologically-confirmed, high-grade glioma(WHO Ⅲ/Ⅳ) who have progressed on temozolomide, or radiotherapy alone, or combined with chemotherapy within 3 months after surgery .
- With measurable or evaluable disease defined by RECIST 1.1 criteria by MRI scan.
- Eastern Cooperative Oncology Group Performance Status (ECOG P.S.) of ≤ 2
- Life expectancy ≥3 months.
- No evidence of serious cardiopulmonary function damage, postoperative complication and hemorrhage on the baseline.
- No history of cerebral embolism, cerebral hemorrhage and serious hypertension disease.
- Recovery from the effects of prior therapy, including the following: 4 weeks from cytotoxic agents (except 6 weeks from nitrosoureas and mitomycin), radiotherapy and surgery.
Patients have adequate organ function as defined by the following criteria:
- Hemoglobin (HGB) ≥90g/L
- Absolute neutrophil count (ANC) ≥1.5×109/L
- White blood cell (WBC) ≥3.0×109/L
- Platelet count ≥80×109/L
- Alanine aminotransferase(ALT) and Aspartate aminotransferase (AST) of ≤2.5 upper normal limitation (UNL) or ≤5 UNL in case of liver metastasis
- Creatinine (Cr) of ≤1.25 UNL or creatinine clearance(Ccr) > 45 ml/min.
- Patients will take contraceptive measures for the duration of the treatments and 8 weeks after the last treatment.
- With written informed consent signed voluntarily by patients themselves.
Exclusion Criteria:
- Pregnant or lactating women.
- Inadequately controlled hypertension (defined as systolic blood pressure > 140 and/or diastolic blood pressure > 90 mmHg on antihypertensive medications).
- New York Heart Association (NYHA) Grade II or greater congestive heart failure.
- Coronary heart disease greater than ClassⅠ;Ⅰ-level arrhythmia (including QT interval prolongation≥440 ms) together with ClassⅠcardiac dysfunction
- Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction).
- Abnormal Coagulation (international normalized ratio>1.5, prothrombin time>UNL+4s,activated partial thromboplastin time>1.5 UNL), with tendency of bleeding.
- Currently receive thrombolytic and anticoagulation therapy
- History of pneumorrhagia(CTCAE grade ≥2 ) or other parts hemorrhage(CTCAE grade ≥3 ) within 4 weeks prior to treatment.
- History of artery thrombosis and phlebothrombosis, such as cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism, within 6 month prior to treatment.
- Medical history of clinically significant thrombosis (bleeding or clotting disorder), excluding warfarin(1mg po qd) and aspirin(80-100mg po qd) for prevention under INR≤1.5.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Apatinib+Irinotecan
Apatinib and irinotecan in treating patients with recurrent high-grade glioma,who have progressed on temozolomide, or radiotherapy alone, or combined with chemotherapy within 3 months after surgery .
|
Patients were administered at apatinib (850mg po qd) and irinotecan(125mg/m2 d1,8) intravenously every three weeks for up to 6 cycles.Maintenance apatinib (500mg po qd) was administered until disease progression or unacceptable toxicity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: From enrollment to progression of disease. Estimated about 6 months
|
The length of time from enrollment until the time of progression of disease (PFS, progression-free survival)
|
From enrollment to progression of disease. Estimated about 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: From enrollment to death of patients. Estimated about 1 year
|
The length of time from enrollment until the time of death (OS, overall survival)
|
From enrollment to death of patients. Estimated about 1 year
|
Objective Response Rate (ORR)
Time Frame: From enrollment to 2 months after treatment
|
clinical response of treatment according to RESIST v1.1 criteria (ORR, objective response rate)
|
From enrollment to 2 months after treatment
|
Disease Control Rate (DCR)
Time Frame: From enrollment to 2 months after treatment
|
Disease control rate is defined as the number of patients with a best overall response of complete response (CR), partial response (PR), or stable disease (SD) based on RESIST v1.1 criteria.
|
From enrollment to 2 months after treatment
|
Duration of Response(DOR)
Time Frame: From first documented CR or PR until disease progression or death(up to 1 year)
|
As measured by RECIST 1.1 criteria and defined as the time from the first documented CR or PR until disease progression or death from any cause.
|
From first documented CR or PR until disease progression or death(up to 1 year)
|
Quality of life (QOL)
Time Frame: up to 1 year
|
Quality of life (QOL) will be measured using the EORTC QLQ-C30 questionnaires,which consists of 28 questions with answers that range from 1 (Not At All) to 4 (Very Much) and 2 questions that range from 1 (Very Poor) to 7 (Excellent)
|
up to 1 year
|
Incidence of treatment-related adverse events
Time Frame: up to 1 year
|
The incidence of treatment-related adverse events were graded with the use of the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
|
up to 1 year
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Protein Kinase Inhibitors
- Topoisomerase I Inhibitors
- Irinotecan
- Apatinib
Other Study ID Numbers
- AI-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on High-grade Glioma
-
James FelkerConnor's Cure; Ellie Kavalieros Fund; Translational Brain Tumor Research FundActive, not recruitingNewly Diagnosed Pediatric Pontine Glioma | Newly Diagnosed Pediatric High Grade Glioma | Recurrent Pediatric High Grade Glioma | Recurrent Pediatric Low Grade GliomaUnited States
-
National Cancer Institute (NCI)RecruitingGlioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade GliomaUnited States
-
Maastricht Radiation OncologyMaastricht University Medical Center; Ziekenhuis Oost-Limburg; Zuyderland Medisch...Active, not recruitingHigh Grade Glioma | Low-grade GliomaNetherlands
-
The University of Texas Health Science Center at...CompletedHIGH GRADE GLIOMAUnited States
-
Hospital del Río HortegaCompletedGlioma | Glioblastoma | Low-grade Glioma | Glioma, Malignant | High-grade GliomaSpain
-
Hospices Civils de LyonCompletedLow Grade Glioma (LGG) | High Grade Glioma (HGG)France
-
Hospices Civils de LyonTerminatedLow Grade Glioma (LGG), High Grade Glioma (HGG)France
-
University of California, San FranciscoNovartis Pharmaceuticals; Pediatric Brain Tumor Foundation; The Lilabean Foundation...RecruitingHigh Grade Glioma | Low-grade Glioma | Recurrent World Health Organization (WHO) Grade II GliomaUnited States
-
BioMimetix JV, LLCNational Cancer Institute (NCI); Duke Cancer InstituteActive, not recruitingGlioblastoma | High Grade Glioma | Astrocytoma, Grade IIIUnited States
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI); Treovir, LLC; American Lebanese Syrian Associated...Not yet recruitingNeoplasms | Malignant Glioma of Brain | Glioblastoma Multiforme | High Grade Glioma | Giant Cell Glioblastoma | High-grade Glioma | Anaplastic Astrocytoma of Brain | Anaplastic GliomaUnited States
Clinical Trials on Apatinib and Irinotecan
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
Sun Yat-sen UniversityRecruiting
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Not yet recruiting
-
Tianjin Medical University Cancer Institute and...Completed
-
Zhejiang Cancer HospitalUnknown
-
Fujian Cancer HospitalUnknownAdvanced Gastric Cancer Adenocarcinoma of Esophagogastric JunctionChina
-
China Medical University, ChinaGeneral Hospital of Shenyang Military Region; Shengjing Hospital; The People's... and other collaboratorsUnknownMetastatic Gastric AdenocarcinomaChina
-
Beijing Chest HospitalJiangsu HengRui Medicine Co., Ltd.UnknownSmall Cell Lung Cancer
-
LaNova Medicines Zhejiang Co., Ltd.Not yet recruitingLocally Advanced or Metastatic GC and GCJ Adenocarcinoma
-
Jiangsu HengRui Medicine Co., Ltd.Unknown